Food Allergy

In the OUTMATCH stage 2 randomized trial, omalizumab achieved greater intention-to-treat success than multiallergen oral immunotherapy.

FDA epinephrine updates, phase 3 HAE data on lonvo-z, and new food allergy prevention research from April through June 2026.

From a one-time CRISPR therapy cutting HAE attacks by 87% to CSU biomarkers and emerging ILIT research, here are the 5 allergy stories worth catching up on from May 2026.

Marcus Shaker, MD, discusses early allergen introduction, food allergy prevention, and the role of routine testing at EAC 2026.

In this Q&A, Christopher Brooks, MD, discusses advancing research on intralymphatic immunotherapy for environmental and, more recently, food allergies.

In recognition of Food Allergy Awareness Month, Brooks discusses food challenges, omalizumab, oral immunotherapy, and persistent gaps in food allergy management.

FDA updates, phase 3 CRISPR data in HAE, and emerging food allergy prevention strategies defined allergy and immunology news in April 2026.

Evidence from 3 recent studies explores microbiome modulation, early allergen exposure, and immune tolerance as pathways for food allergy prevention.

Early allergen introduction, microbiome research, and immune programming studies suggest food allergy prevention may begin during infancy.

Engel discusses ADAA 2026 findings identifying fear of social judgment as a distinct component of food allergy–related anxiety in adolescents.

Stay updated with the latest healthcare breakthroughs, including FDA actions, in this week’s essential news roundup.

FDA approvals, new HAE guidance, epinephrine access shifts, and phase 3 peanut patch data defined major allergy developments across Q1 2026.

March 2026 allergy news: FDA label updates, mastocytosis NDA, and promising data for peanut patch, remibrutinib, and CRSwNP biologics.

New research identifies dietary epitopes driving oral tolerance, offering insight into Treg responses, early exposure, and future food allergy therapies.

Angkeow discusses a recent study finding that PhIP-Seq analysis links diverse IgG responses to food allergy phenotypes.

In this Q&A, Fleischer discusses clinically meaningful gains in peanut allergy desensitization, strong response rates, and the path toward FDA submission for VP250.

Phase 3 VITESSE data show VIASKIN peanut patch improves tolerance in most children, with high adherence and a favorable safety profile.

Data presented at AAAAI 2026 showed that adding dupilumab to omalizumab-facilitated oral immunotherapy improved desensitization and reduced gastrointestinal adverse events.

Wood discussed the potential of BTK inhibition for peanut allergy and beyond.

This HCPLive Five captures 5 interviews conducted on-site at AAAAI 2026.

Wood discussed factors that go into shared decision making for multi-food allergy.

McWilliam discussed findings from the TreEat study at AAAAI 2026.

At AAAAI 2026, Torres highlighted phase 3 peach immunotherapy research, nanostructure preclinical models, and a phase 2 prebiotic trial for LTP allergy.

Wood discussed the latest long term data from OUtMATCHat AAAAI 2026.